SecuritySPPI / Spectrum Pharmaceuticals, Inc. (84763A108)
IndustryPharmaceutical Preparations
Common Shares Outstanding105,958,838 shares (as of 2018-06-30)
Total Insiders14
Total Directors10
Total Officers5

Stock Insider Trading (from SEC Form 4)

Spectrum Pharmaceuticals, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

SPPI / Spectrum Pharmaceuticals, Inc. insiders include Vyas Dolatrai, McGahan Keith M, Welles Bernice R Krassner Stuart Mitchell, SHROTRIYA RAJESH C MD, MAIDA ANTHONY E III, COHEN RAYMOND W, GUSTAFSON KURT A, ALLEN LEE F MD PhD, Riga Thomas J, LENAZ LUIGI MD, Turgeon Joseph W., Ashton William, and Gagnon Gilles, .

Insider Roster

Insider Dir Off 10% Shares Owned
McGahan Keith M SVP and Chief Legal Officer
X 106,962
Riga Thomas J EVP, COO & CCO
X 247,332
Welles Bernice R Director
X 10,000
COHEN RAYMOND W Director
X 38,850
Krassner Stuart Mitchell Director
X 67,944
Ashton William Director
X 10,000
MAIDA ANTHONY E III Director
X 32,988
Vyas Dolatrai Director
X 47,079
Gagnon Gilles Director
X 82,500
LENAZ LUIGI MD Director
X 109,077
SHROTRIYA RAJESH C MD Director
X 4,155,289
Turgeon Joseph W. CEO & President, Director
X X 316,509
GUSTAFSON KURT A EVP & Chief Financial Officer
X 193,739
ALLEN LEE F MD PhD Chief Medical Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-08 4 McGahan Keith M S X D 20.96 -437 106,962 2,241,924
2018-06-25 4 Riga Thomas J S X D 18.7557 -235 247,332 4,638,885
2018-06-18 4 Gagnon Gilles A D 10,000 82,500
2018-06-18 4 Vyas Dolatrai A D 10,000 47,079
2018-06-18 4 MAIDA ANTHONY E III A D 10,000 32,988
2018-06-18 4 Ashton William A D 10,000 10,000
2018-06-18 4 Krassner Stuart Mitchell A D 10,000 67,944
2018-06-18 4 COHEN RAYMOND W A D 10,000 38,850
2018-06-18 4 Welles Bernice R A D 10,000 10,000
2018-06-18 4 McGahan Keith M A D 45,000 107,289
2018-05-22 4 LENAZ LUIGI MD M D 1.47 40,000 109,077
2018-05-17 4 Krassner Stuart Mitchell S D 18.94 -21,113 57,944 1,097,459
2018-05-17 4 SHROTRIYA RAJESH C MD By CS Family Trust G I 362,926 4,155,289
2018-05-17 4 SHROTRIYA RAJESH C MD G D -362,926 3,377,052
2018-05-17 4 SHROTRIYA RAJESH C MD M D 1.47 250,426 3,739,978
2018-05-17 4 SHROTRIYA RAJESH C MD M D 1.43 112,500 3,489,552
2018-05-14 4 COHEN RAYMOND W S D 18.32 -9,275 28,850 528,532
2018-05-14 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.38 -24,014 3,953,015 72,656,416
2018-05-11 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.55 -30,000 3,977,029 69,796,859
2018-05-10 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.13 -30,000 4,007,029 68,640,407
2018-05-14 4 Riga Thomas J S X D 18.101 -3,290 247,555 4,480,993
2018-05-09 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.21 -30,000 4,037,029 65,440,240
2018-05-08 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.11 -30,000 4,067,029 65,519,837
2018-05-07 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.98 -30,000 4,097,029 65,470,523
2018-05-04 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.79 -30,000 4,127,029 69,292,817
2018-05-03 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.01 -30,000 4,157,029 66,554,034
2018-05-02 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.04 -30,000 4,187,029 67,159,945
2018-05-01 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.77 -30,000 4,217,029 66,502,547
2018-04-30 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.36 -30,000 4,247,029 69,481,394
2018-04-27 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.17 -30,000 4,277,029 73,436,588
2018-04-26 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.26 -30,000 4,307,029 74,339,321
2018-04-25 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.26 -30,000 4,337,029 74,857,121
2018-04-24 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.11 -30,000 4,367,029 79,086,895
2018-04-23 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.37 -30,000 4,397,029 80,773,423
2018-04-20 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.67 -30,000 4,427,029 82,652,631
2018-04-19 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 19.18 -30,000 4,457,029 85,485,816
2018-04-18 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 19.71 -30,000 4,487,029 88,439,342
2018-04-17 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.56 -30,000 4,517,029 83,836,058
2018-04-16 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.72 -30,000 4,547,029 85,120,383
2018-04-17 4 Turgeon Joseph W. S X D 19.0014 -11,565 316,509 6,014,114
2018-04-17 4 Riga Thomas J S X D 19.0667 -1,840 250,778 4,781,509
2018-04-16 4 Riga Thomas J S X D 18.595 -3,900 261,618 4,864,787
2018-04-13 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 19.93 -30,000 4,577,029 91,220,188
2018-04-12 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 20.72 -30,000 4,607,029 95,457,641
2018-04-11 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 20.30 -30,000 4,637,029 94,131,689
2018-04-10 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.74 -30,000 4,667,029 82,793,094
2018-04-09 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.01 -12,300 4,697,029 70,502,405
2018-04-06 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.00 -3,686 4,709,329 70,639,935
2018-04-05 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.33 -30,000 4,713,015 72,250,520
2018-04-04 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.01 -30,000 4,743,015 71,192,655
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2

2018-08-11 zacks
Spectrum Pharmaceuticals, Inc. (SPPI - Free Report) incurred an adjusted loss of 21 cents per share in the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 18 cents and the year-ago quarter loss of 11 cents per share. (10-0)

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joe Turgeon on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Q2 2018 Results Earnings Conference Call August 9, 2018 4:30 PM ET (10-0)

Spectrum Pharmaceuticals (SPPI) Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 zacks
Spectrum Pharmaceuticals (SPPI - Free Report) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. (10-0)

Redfin (RDFN) Tops Q2 Earnings and Revenue Estimates

2018-08-09 zacks
Redfin (RDFN - Free Report) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. (10-0)

Invitation Home (INVH) Meets Q2 Earnings Estimates

2018-08-09 zacks
Invitation Home (INVH - Free Report) came out with quarterly earnings of $0.29 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. (10-0)